T&R Biofab Co. Ltd (246710) - Total Assets
Based on the latest financial reports, T&R Biofab Co. Ltd (246710) holds total assets worth ₩83.86 Billion KRW (≈ $56.83 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check cash flow reinvestment rate of T&R Biofab Co. Ltd to assess the company's total reinvestment commitment from operating cash flow.
T&R Biofab Co. Ltd - Total Assets Trend (2015–2024)
This chart illustrates how T&R Biofab Co. Ltd's total assets have evolved over time, based on quarterly financial data. Explore T&R Biofab Co. Ltd (246710) investment intensity to see how much of total assets are deployed in long-term investments.
T&R Biofab Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
T&R Biofab Co. Ltd's total assets of ₩83.86 Billion consist of 26.7% current assets and 73.3% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩16.67 Billion | 16.9% |
| Accounts Receivable | ₩2.20 Billion | 2.2% |
| Inventory | ₩4.72 Billion | 4.8% |
| Property, Plant & Equipment | ₩61.33 Billion | 62.3% |
| Intangible Assets | ₩1.33 Billion | 1.4% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how T&R Biofab Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see T&R Biofab Co. Ltd market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: T&R Biofab Co. Ltd's current assets represent 26.7% of total assets in 2024, a decrease from 55.9% in 2015.
- Cash Position: Cash and equivalents constituted 16.9% of total assets in 2024, down from 53.7% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 3.0% in 2015.
- Asset Diversification: The largest asset category is property, plant & equipment at 62.3% of total assets.
T&R Biofab Co. Ltd Competitors by Total Assets
Key competitors of T&R Biofab Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $90.55 Million |
|
Medacta Group SA
SW:MOVE
|
Switzerland | CHF860.76 Million |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.52 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
Xiangyu Medical Co. Ltd. A
SHG:688626
|
China | CN¥3.27 Billion |
|
INKON Life Technology Co Ltd
SHE:300143
|
China | CN¥4.17 Billion |
T&R Biofab Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.42 | 0.85 | 35.42 |
| Quick Ratio | 0.32 | 0.76 | 32.46 |
| Cash Ratio | 0.00 | 0.39 | 0.00 |
| Working Capital | ₩-22.87 Billion | ₩-6.02 Billion | ₩41.62 Billion |
T&R Biofab Co. Ltd - Advanced Valuation Insights
This section examines the relationship between T&R Biofab Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.91 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -1.4% |
| Total Assets | ₩98.45 Billion |
| Market Capitalization | $44.45 Million USD |
Valuation Analysis
Below Book Valuation: The market values T&R Biofab Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: T&R Biofab Co. Ltd's assets decreased by 1.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for T&R Biofab Co. Ltd (2015–2024)
The table below shows the annual total assets of T&R Biofab Co. Ltd from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩98.45 Billion ≈ $66.72 Million |
-1.37% |
| 2023-12-31 | ₩99.82 Billion ≈ $67.64 Million |
+31.44% |
| 2022-12-31 | ₩75.94 Billion ≈ $51.46 Million |
-7.66% |
| 2021-12-31 | ₩82.23 Billion ≈ $55.73 Million |
+69.54% |
| 2020-12-31 | ₩48.51 Billion ≈ $32.87 Million |
+79.07% |
| 2019-12-31 | ₩27.09 Billion ≈ $18.36 Million |
-12.91% |
| 2018-12-31 | ₩31.10 Billion ≈ $21.08 Million |
+228.56% |
| 2017-12-31 | ₩9.47 Billion ≈ $6.42 Million |
-1.27% |
| 2016-12-31 | ₩9.59 Billion ≈ $6.50 Million |
+75.95% |
| 2015-12-31 | ₩5.45 Billion ≈ $3.69 Million |
-- |
About T&R Biofab Co. Ltd
T&R Biofab Co., Ltd. develops and commercializes various regenerative medical technologies. It offers 3D-printed medical devices; and bio-surgical solutions, which includes wound dressing and acellular dermal matrix, as well as biomaterials and biopharmaceuticals. The company was founded in 2013 and is based in Siheung-si, South Korea.